22 Rue Garnier
Neuilly Sur Seine
180 articles with Servier
Wide range of research across tumor types underscores Servier's commitment to discovering novel approaches to addressing difficult-to-treat cancers.
Phase 3 AGILE Data of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia Published in the New England Journal of Medicine
Global Phase 3 trial of TIBSOVO (ivosidenib tablets) met its primary endpoint of event-free survival and all key secondary endpoints, complete remission rate, overall survival, complete remission and complete remission with partial hematologic recovery rate.
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
Servier today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for TIBSOVO.
Phase 3 Data Demonstrate TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
Servier announced Phase 3 data demonstrating that TIBSOVO® in combination with the chemotherapy azacitidine significantly improved event-free survival and overall survival compared to azacitidine plus placebo in adults with previously untreated IDH1-mutated acute myeloid leukemia who are not candidates for intensive chemotherapy.
Servier, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, announced new data in acute myeloid leukemia to be presented at the 63rd Annual Meeting of the American Society of Hematology taking place December 11 – 14, 2021.
Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
Servier, a global pharmaceutical company, announced the global Phase 3 double blinded placebo controlled AGILE study of TIBSOVO in combination with the chemotherapy azacitidine in adults with previously untreated IDH1-mutated acute myeloid leukemia met its primary endpoint of event-free survival.
Servier Announces Promising Phase 1 Data for Vorasidenib in IDH Mutant Low-Grade Glioma Published in Clinical Cancer Research
- Servier today announced that Clinical Cancer Research has published data from its Phase 1 study evaluating single-agent vorasidenib in isocitrate dehydrogenase (IDH) mutant advanced solid tumors, including low-grade glioma.
Servier Presents Updated Translational Data from Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib tablets) in Patients with IDH Mutant Low-Grade Glioma at ASCO 2021
Data suggest short-term treatment with vorasidenib and TIBSOVO reduces tumor cell proliferation, alters epigenetic state, and promotes expression of genes associated with cellular differentiation BOSTON , J
Transaction includes TIBSOVO®, co-commercialization responsibilities for Bristol Myers Squibb's IDHIFA® as well as a strong oncology pipeline of Phase 3 and early-stage assets
Agios Receives $1.8 Billion in Upfront Cash to Focus on Accelerating and Expanding its Genetically Defined Disease Portfolio Agios Enters Into Agreement to Repurchase Approximately 10% of Its Outstanding Shares from Bristol-Myers Squibb for $344.5 Million
MiNA eligible for up to 220 M€ in upfront, development and commercial milestone payments for first target.
Taiho Oncology and Servier To Present Data on LONSURF® (trifluridine and tipiracil) at 2021 ASCO Gastrointestinal Cancers Symposium (ASCO GI)
Taiho Oncology, Inc. and Servier today announced that data for LONSURF ® (trifluridine and tipiracil) in previously treated patients with metastatic gastric cancer (mGC) and metastatic gastroesophageal junction adenocarcinoma (mGEJC) will be presented during the 2021 American Society of Clinical Oncology Gastrointestinal Cancers
- Transaction includes commercial, clinical and research-stage oncology portfolio and employees for up to $2 Billion plus royalties - Includes Agios' marketed medicine TIBSOVO® and a strong oncology pipeline of Phase 3 and early-stage assets - Acquisition in-line with Servier's strategic ambition to become a recognized and innovative player in oncology, supported by unique drug discovery capabilities
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a collaboration with Servier, an independent global pharmaceutical company, to reinvent their R&D clinical development processes and support their long-term R&D success. Servier has ambitious plans for growth a
Servier, an independent international pharmaceutical company, has awarded the 2020 Servier Golden Ticket at MBC BioLabs to Telo Therapeutics, a biotechnology company focusing on working on s
Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors
Precision BioSciences, Inc. announced the companies have added two additional hematological cancer targets beyond CD19 and two solid tumor targets to its CAR T development and commercial license agreement.
Servier, an independent international pharmaceutical company, today announced that it has completed the acquisition of Symphogen A/S. Symphogen will now function as Servier's antibody center of excelle
3/2/2020The month of February ended with a flurry of clinical trial announcements. Here’s a look.
Cellectis grants additional rights to Servier to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19, including ALLO-501A
A complete listing of this year's Servier abstracts* are available on the ASH website.